BioCardia, Inc. Announces Completion of FDA Pre‑Submission for Helix Catheter

What Happened BioCardia, Inc. (BCDA) announced on October 1, 2026 (via a press release attached to a Form 8‑K) that it has completed a revised Pre‑Submission to the FDA Center for Devices and Radiological Health (CDRH) under the agency's Q‑Submission program. The submission concerns the company’s Helix Catheter intended for therapeutic and diagnostic agent delivery to the heart.

Key Details

• Date filed: Form 8‑K and press release dated October 1, 2026.
• Regulator/Program: Revised Pre‑Submission submitted to FDA CDRH under the Q‑Submission program.
• Product: Helix Catheter — for therapeutic and diagnostic agent delivery to the heart.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8‑K.

Why It Matters This filing documents a regulatory step forward for BioCardia’s Helix Catheter. Completing a revised pre‑submission is part of the FDA engagement process that can yield formal feedback on study design, testing and regulatory pathway — information that can shape future studies, submissions and timelines toward approval. The Form 8‑K does not report clinical results, financial impacts, or a submission for market approval; it only confirms the company has advanced its FDA interactions. Investors should view this as a procedural milestone in the device’s development rather than evidence of regulatory approval or guaranteed commercial progress.